Characteristics and Outcomes of Patients with Heart Failure Admitted with Covid-19 in a Cohort Study from Southeast Michigan

Introduction: Cardiovascular comorbidities confer worse outcomes for patients with Coronavirus disease 2019 (COVID-19), but the impact of heart failure (HF) with preserved (HFpEF) and reduced (HFrEF) ejection fraction has not been well characterized The aim herein is to examine outcomes in COVID-19 patients with and without HF Methods: Patients (n = 437) consecutively admitted with COVID-19 were categorized according to the presence vs absence of HF and subcategorized according to HFpEF and HFrEF (EF 0 05) and there were no differences in inflammatory markers (ferritin, D-dimer, CRP, LDH) Independent predictors of inpatient mortality included: HFpEF (adjOR 2 55 (1 37-4 76)), age > 65 years (adjOR 3 00 (1 66-5 43), African American race (adjOR 1 82 (1 00-3 30)), Other race (adjOR 2 34 (1 02-5 37), p = 0 043), cerebrovascular disease (adjOR 3 07 (1 54-6 10), p = 0 001), and chronic hypoxic respiratory failure [adjOR 3 02 (1 19-7 62], p = 0 019)], whereas HFrEF was not (adjOR 1 58 (0 77-3 23) Discussion: HF is prevalent in patients admitted with COVID-19 Patients with HFpEF had 2 6-fold higher mortality than those without HF and greater burdens of inpatient complications Patients with HFpEF with COVID19 may warrant closer outpatient monitoring and a lower threshold for admission